|
🦁
|
Loss of Functional Suppression by CD4+CD25+ Regulatory T Cells in Patients with Multiple Sclerosis
V. Viglietta,
C. Baecher-Allan,
H. Weiner,
D. Hafler
|
10 |
2004 |
10
🦁
|
|
🐜
|
Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis.
13 auth.
R. Fox,
David H. Miller,
J. Phillips,
M. Hutchinson,
E. Havrdová,
M. Kita,
Minhua Yang,
K. Raghupathi,
M. Novas,
M. Sweetser,
...
V. Viglietta,
K. Dawson,
C. Sindic
|
10 |
2012 |
10
🐜
|
|
🐬
|
Human CD4+CD25+ regulatory T cells.
C. Baecher-Allan,
V. Viglietta,
D. Hafler
|
8 |
2004 |
8
🐬
|
|
🐜
|
Self-antigen tetramers discriminate between myelin autoantibodies to native or denatured protein
26 auth.
K. O’Connor,
K. McLaughlin,
P. Jager,
T. Chitnis,
E. Bettelli,
Chenqi Xu,
W. Robinson,
S. Cherry,
A. Bar-Or,
B. Banwell,
H. Fukaura,
T. Fukazawa,
S. Tenembaum,
S. Wong,
Norma P. Tavakoli,
...
Z. Idrissova,
V. Viglietta,
K. Rostásy,
D. Pohl,
R. Dale,
M. Freedman,
L. Steinman,
G. Buckle,
V. Kuchroo,
D. Hafler,
K. Wucherpfennig
|
8 |
2007 |
8
🐜
|
|
🐬
|
Inhibition of Human CD4+CD25+high Regulatory T Cell Function1
C. Baecher-Allan,
V. Viglietta,
D. Hafler
|
8 |
2002 |
8
🐬
|
|
🐜
|
Antigen microarrays identify unique serum autoantibody signatures in clinical and pathologic subtypes of multiple sclerosis
12 auth.
F. Quintana,
M. Farez,
V. Viglietta,
A. Iglesias,
Y. Merbl,
G. Izquierdo,
...
M. Lucas,
A. Basso,
S. Khoury,
C. Lucchinetti,
I. Cohen,
H. Weiner
|
7 |
2008 |
7
🐜
|
|
🐜
|
Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post-hoc and subgroup analysis
9 auth.
G. Giovannoni,
S. Cook,
K. Rammohan,
P. Rieckmann,
P. Sørensen,
P. Vermersch,
...
A. Hamlett,
V. Viglietta,
S. Greenberg
|
7 |
2011 |
7
🐜
|
|
🐜
|
Natalizumab treatment is associated with peripheral sequestration of proinflammatory T cells
7 auth.
P. Kivisäkk,
B. Healy,
V. Viglietta,
F. Quintana,
M. A. Hootstein,
H. Weiner,
...
S. Khoury
|
7 |
2009 |
7
🐜
|
|
🐜
|
Age-Dependent B Cell Autoimmunity to a Myelin Surface Antigen in Pediatric Multiple Sclerosis1
24 auth.
K. McLaughlin,
T. Chitnis,
J. Newcombe,
Bettina Franz,
Julia Kennedy,
Shannon L. McArdel,
J. Kuhle,
L. Kappos,
K. Rostásy,
D. Pohl,
...
D. Gagné,
J. Ness,
S. Tenembaum,
K. O’Connor,
V. Viglietta,
S. Wong,
Norma P. Tavakoli,
J. de Seze,
Z. Idrissova,
S. Khoury,
A. Bar-Or,
D. Hafler,
B. Banwell,
K. Wucherpfennig
|
7 |
2009 |
7
🐜
|
|
🐜
|
Safety and tolerability of cladribine tablets in multiple sclerosis: the CLARITY (CLAdRIbine Tablets treating multiple sclerosis orallY) study
13 auth.
S. Cook,
P. Vermersch,
G. Comi,
G. Giovannoni,
K. Rammohan,
P. Rieckmann,
P. Sørensen,
A. Hamlett,
M. Miret,
J. Weiner,
...
V. Viglietta,
B. Musch,
S. Greenberg
|
6 |
2011 |
6
🐜
|
|
🐜
|
Delayed-Release Dimethyl Fumarate and Pregnancy: Preclinical Studies and Pregnancy Outcomes from Clinical Trials and Postmarketing Experience
16 auth.
R. Gold,
J. Phillips,
E. Havrdová,
A. Bar-Or,
L. Kappos,
Norman N. Kim,
Tim Thullen,
Patricia Valencia,
L. Oliva,
M. Novas,
...
Jie Li,
M. Sweetser,
M. Sweetser,
N. Kurukulasuriya,
V. Viglietta,
R. Fox
|
6 |
2015 |
6
🐜
|
|
🦁
|
CTLA4Ig treatment in patients with multiple sclerosis
10 auth.
V. Viglietta,
K. Bourcier,
G. Buckle,
B. Healy,
H. Weiner,
D. Hafler,
...
S. Egorova,
C. Guttmann,
J. Rusche,
S. Khoury
|
6 |
2008 |
6
🦁
|
